Auris Medical : development of novel pharmaceutical therapies to prevent or treat severe inner ear disorders like tinnitus and hearing loss     Print Page | Close Window

Investor Relations

We at Auris Medical are dedicated to developing novel pharmaceutical products for the treatment of inner ear disorders.

We have two lead clinical-stage product candidates: Keyzilen® (AM-101), which is being developed for the treatment of acute inner ear tinnitus, and AM-111, being developed for the treatment of acute inner ear hearing loss and has been granted orphan drug status by the FDA and the EMA.

AM-125 is being developed for the treatment of vestibular disorders.

In addition, we are pursuing early stage projects for the treatment of tinnitus.

 

View more

 

There are currently no events scheduled.


Various statements that Auris Medical Holding makes on this website about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The terms 'may,' 'will,' 'could,' 'anticipate,' 'plan,' 'continue,' 'project,' 'intend,' 'estimate,' 'believe,' 'expect,' and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors.

In addition, any forward-looking statements represent the company's views only as of the date such statements are made and should not be relied upon as representing our views as of any subsequent date. While the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, even if its views change. Therefore, you should not rely on these forward-looking statements as representing the company's views as of any date subsequent the date such statements are made.